Following a Priority Review, the US FDA has approved Israel TEVA’s Leukemia treatment, TRISENOX® (arsenic trioxidec). Trisenox is to be used in combination with tretinoin for treatment of recently-diagnosed low-risk adults with acute promyelocytic leukemia (APL).
http://www.jewishpress.com/news/us-news/fda-approves-teva-leukemia-treatment/2018/01/15/